At1g78910 Antibody
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
Based on the provided search results, there appears to be a discrepancy between the requested "At1g78910 Antibody" (an Arabidopsis thaliana gene identifier) and the research materials available, which focus on therapeutic antibodies targeting human proteins like PD-L1, 4-1BB, and AT1R. Below are scientifically rigorous FAQs structured for antibody research methodology, leveraging principles from the available studies:
Advanced Research Questions
How to engineer antibodies that overcome resistance in immunologically cold tumors?
The PD-L1×4-1BB bispecific antibody case ( ) demonstrates:
-
Tetravalent architecture (2+2 configuration) balances PD-L1 anchoring (KD ≈1 nM) and 4-1BB activation (KD ≈10 nM)
-
Key metrics in resistant models:
-
≥3-fold increase in tumor-infiltrating CD8+ T cells
-
CD8+/Treg ratio >5:1 in TME
-
Complete regression in 40% of ICI-refractory cases
-
How to resolve discrepancies between in vitro binding and in vivo efficacy?
The ATG-101 study ( ) employed:
-
Step 1: High-throughput MFI screening (30+ concentrations)
-
Step 2: Ex vivo T-cell activation assays with PD-L1+ tumor cells
-
Step 3: Semimechanistic modeling correlating receptor occupancy (EC₉₀=2 mg/kg) with tumor growth inhibition
What controls are essential when assessing antibody-induced fibrosis?
From the AT1R autoantibody model ( ):
| Control Group | Purpose | Key Exclusion Criterion |
|---|---|---|
| Empty membrane | Adjuvant effects | <5% MFI vs. target |
| CD4+/B-cell KO | T/B-cell dependence | No perivascular infiltration |
| Species ortholog | Cross-reactivity | <20% DMR signal vs. human |
